Biliary Atresia Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global biliary atresia treatment market size is expected to be valued at US$1.1 billion in 2026 and projected to reach US$1.8 billion by 2033, growing at a CAGR of 7.3% between 2026 and 2033, driven by continued reliance on surgical intervention, expanding pharmacological treatment options for biliary atresia, and increasing demand for post-procedure management of cholestatic complications.

Biliary atresia remains a leading cause of pediatric liver transplantation, sustaining demand for surgical intervention and subsequent pharmacological care. Continued development and regulatory approval of therapies targeting cholestatic complications are further expanding treatment options and supporting market growth across developed and emerging healthcare markets.

Drivers - Biliary Atresia's Status as the Leading Cause of Pediatric Liver Transplantation

Biliary atresia remains the most common cause of end-stage liver disease necessitating liver transplantation among infants and young children, with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) continuing to identify this rare congenital condition as the leading indication for pediatric liver transplant procedures worldwide. The Organ Procurement and Transplantation Network (OPTN) continues to track pediatric liver transplant volumes across accredited transplant centers, reflecting the condition's substantial contribution to overall pediatric transplant demand.

Early diagnosis and timely surgical intervention through the Kasai portoenterostomy procedure remain critical to delaying or avoiding transplantation, a clinical priority that the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) continues to emphasize through updated diagnostic and treatment guidelines. This structurally embedded relationship between biliary atresia diagnosis and downstream surgical and transplant intervention continues to sustain consistent treatment demand across the global biliary atresia treatment market irrespective of broader macroeconomic healthcare spending fluctuations.

Expanding Pharmacological Treatment Options for Cholestatic Complications

Growing clinical availability of pharmacological therapies targeting bile acid metabolism and cholestatic pruritus continues to expand treatment options for biliary atresia patients both before and after surgical intervention. The U.S. Food and Drug Administration (FDA)'s approval of ileal bile acid transporter (IBAT) inhibitor therapies for related pediatric cholestatic liver conditions has meaningfully advanced the broader treatment paradigm for bile acid-related pediatric liver disease, supporting continued clinical investigation of similar mechanisms in biliary atresia patients.

Companies such as Mirum Pharmaceuticals and Ipsen, including its Albireo Pharma subsidiary, continue to expand clinical evidence and explore potential label indications for bile acid-modulating therapies within the broader pediatric cholestatic liver disease treatment landscape. As pharmacological options expand beyond conventional ursodeoxycholic acid therapy, physicians have access to additional treatment approaches for managing biliary atresia-related complications, supporting prescription demand across the treatment continuum.

Restraint - Rarity of the Condition Limiting Clinical Trial Enrollment

Biliary atresia's status as a rare pediatric disease, affecting a comparatively small number of infants globally each year, continues to constrain clinical trial enrollment and slow the pace of new therapy development compared with more prevalent disease categories. Pharmaceutical companies developing biliary atresia-specific therapies face inherently limited patient recruitment pools, extending clinical development timelines and increasing per-patient trial costs. This rarity-driven constraint continues to concentrate research and development investment among a small number of specialized pharmaceutical companies willing to navigate the extended timelines and elevated per-patient costs associated with rare pediatric liver disease drug development.

High Costs Associated with Liver Transplantation and Post-Transplant Care

Liver transplantation, the leading treatment category for biliary atresia patients who do not achieve adequate bile drainage following the Kasai procedure, carries substantial costs spanning surgical intervention, extended hospitalization, and lifelong post-transplant immunosuppressive therapy. This cost burden creates meaningful access barriers for families in healthcare systems with limited transplant reimbursement coverage, particularly across emerging markets where pediatric transplant center capacity remains limited. Healthcare systems must balance the clinical necessity of transplantation against significant resource constraints, a tension that continues to limit treatment access in regions lacking robust pediatric transplant infrastructure and reimbursement support.

Opportunities - Development of Emerging Therapies Targeting Biliary Atresia Disease Progression

Continued clinical trial investment in emerging therapies specifically targeting biliary atresia's underlying inflammatory and fibrotic disease processes presents a significant opportunity for pharmaceutical companies to expand treatment options beyond surgical intervention and symptomatic pharmacological management. Companies, including Mirum Pharmaceuticals and Intercept Pharmaceuticals, continue to advance clinical development programs targeting bile acid signaling pathways implicated in pediatric cholestatic liver disease progression.

As clinical evidence supporting these emerging mechanisms continues to accumulate, and as regulatory agencies continue to demonstrate willingness to evaluate therapies for rare pediatric liver conditions under expedited review pathways, pharmaceutical companies with differentiated, disease-modifying therapeutic candidates are positioned to capture meaningful incremental demand within this rapidly expanding treatment category, potentially reducing the proportion of patients who progress to transplant-requiring end-stage liver disease over the forecast period.

Expansion of Newborn Screening and Early Diagnosis Programs

Growing implementation of newborn stool color card screening programs and other early diagnosis initiatives presents a substantial opportunity to improve biliary atresia detection timing, directly improving Kasai procedure success rates and long-term patient outcomes. Japan's pioneering stool color card screening program, developed following the country's foundational role in developing the Kasai portoenterostomy procedure itself, continues to demonstrate measurable improvement in early diagnosis rates that other countries increasingly seek to replicate.

As additional countries across Asia Pacific and other regions continue adopting similar newborn screening protocols, earlier diagnosis is expected to improve Kasai procedure success rates and potentially reduce longer-term transplantation demand, creating sustained opportunity for diagnostic technology providers and pharmaceutical companies supplying the broader biliary atresia treatment continuum from diagnosis through post-surgical pharmacological management.

Treatment Type Analysis

Liver transplantation is expected to account for an estimated 46% share of the global biliary atresia treatment market in 2026, a position anchored in its status as the definitive treatment for patients who fail to achieve adequate bile drainage following the Kasai portoenterostomy procedure or who develop progressive liver failure despite successful initial surgery. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) continues to identify biliary atresia as the leading indication for pediatric liver transplantation worldwide, reinforcing this treatment category's substantial market position.

Transplantation carries the highest per-patient cost among biliary atresia treatment categories, spanning surgical intervention, extended hospitalization, and lifelong post-transplant management, contributing to its leading revenue share despite representing a smaller share of overall patient volume compared with initial Kasai procedure intervention. As transplant surgical techniques and post-transplant care protocols continue advancing, liver transplantation is expected to retain its leading treatment type position, even as emerging therapies continue gaining share at a faster relative pace.

Disease Type Analysis

Isolated, or perinatal, biliary atresia represented the leading disease type segment, reflecting its status as the substantially more common clinical presentation compared with syndromic forms associated with other congenital anomalies. Clinical literature published in peer-reviewed pediatric gastroenterology journals continues to document that the isolated perinatal form accounts for the significant majority of diagnosed biliary atresia cases, typically presenting with progressive jaundice and acholic stools in the weeks following birth without other associated congenital malformations. This higher case volume directly translates into greater overall treatment demand across the diagnostic, surgical, and pharmacological management continuum associated with this disease type.

As newborn screening programs continue improving early detection rates for the isolated perinatal presentation specifically, this disease type is expected to retain its leading position, even as syndromic biliary atresia cases benefit from improving prenatal and genetic diagnostic capability.

North America Biliary Atresia Treatment Market Trends

North America is expected to dominate the global biliary atresia treatment Market, supported by highly specialized pediatric hepatology centers, widespread newborn screening programs for neonatal cholestasis, and one of the world's largest pediatric liver transplantation networks. The region benefits from strong reimbursement systems, early referral pathways, and rapid adoption of advanced therapeutics for rare pediatric liver diseases.

According to the U.S. Health Resources and Services Administration (HRSA), more than 10,000 organ transplants were performed in children in the U.S. between 2013 and 2022, with liver transplantation representing a significant proportion. The Organ Procurement and Transplantation Network (OPTN) reported over 10,600 liver transplants in the U.S. during 2026, demonstrating continued expansion in transplant capacity. Additionally, the FDA's orphan drug incentives and increasing clinical trials for rare cholestatic liver diseases continue to accelerate innovation. These factors collectively support North America's leading position in the global market.

U.S. Biliary Atresia Treatment Market Trends

The U.S dominates the North American market and is expected to reach approximately US$0.37 billion by 2026, driven by advanced pediatric liver disease management and extensive transplantation infrastructure. Biliary atresia affects approximately 1 in every 8,000–18,000 live births in the U.S., according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The country has more than 120 active liver transplant programs, with numerous dedicated pediatric transplant centers. According to OPTN, the U.S. performed over 10,600 liver transplants in 2026, while HRSA continues to support national organ donation initiatives that improve transplant availability. The presence of leading pharmaceutical companies conducting clinical trials in rare cholestatic liver diseases, combined with favorable reimbursement and widespread access to Kasai portoenterostomy and pediatric transplantation, continues to strengthen the U.S. market.

Canada Biliary Atresia Treatment Market Trends

Canada is projected to be the fastest-growing country in North America, with an expected CAGR of 7.8% during 2026–2033. The country has strengthened centralized pediatric liver care through institutions such as The Hospital for Sick Children (SickKids) and CHU Sainte-Justine. According to the Canadian Institute for Health Information (CIHI), organ transplantation activity has steadily increased, supported by improvements in donor registration and transplantation programs. Canada also continues to expand newborn screening and pediatric specialty care, enabling earlier diagnosis of biliary atresia. Government investments in rare disease strategies, including funding announced under Canada's National Strategy for Drugs for Rare Diseases, are improving patient access to innovative therapies. Increasing collaboration between academic hospitals and biotechnology companies is expected to further support growth in the country's biliary atresia treatment market.

Europe Biliary Atresia Treatment Market Trends

Europe remains an important region in the global biliary atresia treatment market because of its universal healthcare systems, centralized pediatric hepatology services, and well-established pediatric liver transplant programs. The region has developed standardized referral pathways through organizations such as the European Reference Networks (ERN), allowing infants with biliary atresia to receive timely diagnosis and specialized treatment. According to the Council of Europe, over 7,000 liver transplants are performed annually across Europe, while Eurotransplant continues to improve organ allocation efficiency among member countries. European countries also actively participate in rare disease research under EU-supported initiatives, accelerating development of novel therapies for pediatric cholestatic liver disorders. Strong regulatory support for orphan medicines through the European Medicines Agency (EMA) and increasing clinical research continue to reinforce Europe's importance within the global biliary atresia treatment landscape.

Germany Biliary Atresia Treatment Market Trends

Germany is expected to remain Europe's largest market and is projected to reach approximately US$0.09 billion by 2026. Germany possesses one of Europe's largest transplant infrastructures, supported by highly specialized pediatric liver centers including Hannover Medical School and Charité Berlin. According to Eurotransplant and the German Organ Transplantation Foundation (DSO), Germany continues to perform several hundred liver transplants annually despite donor shortages.

The country also benefits from universal health insurance, allowing broad access to Kasai portoenterostomy, liver transplantation, and long-term follow-up care. Germany's strong clinical research environment, participation in European Reference Networks for rare liver diseases, and increasing adoption of innovative orphan drugs continue to strengthen its leadership position in the European biliary atresia treatment market.

France Biliary Atresia Treatment Market Trends

France is projected to be the fastest-growing market in Europe, expanding at an expected CAGR of 7.6% during 2026–2033. France has established nationally coordinated pediatric liver disease care through specialized university hospitals and transplant centers. According to the Agence de la Biomédecine, France continues to increase organ transplantation activity through national donor awareness campaigns and improved allocation systems.

The country's National Rare Disease Plans have significantly expanded funding for research, diagnosis, and treatment of rare pediatric disorders, including biliary atresia. France also actively participates in multinational European clinical trials evaluating new therapies for cholestatic liver diseases. Continued government investment in rare disease infrastructure and pediatric hepatology services is expected to accelerate market growth throughout the forecast period.

Asia Pacific Biliary Atresia Treatment Market Trends

Asia Pacific is expected to be the fastest-growing region in the global biliary atresia treatment market due to higher disease incidence, expanding neonatal healthcare infrastructure, increasing pediatric liver transplantation capacity, and rising government investment in rare disease management. Several Asian countries report a higher incidence of biliary atresia than Western populations, creating sustained demand for early diagnosis and surgical intervention. Japan, Taiwan, South Korea, China, and India continue to strengthen pediatric hepatology services and liver transplantation programs.

According to the World Health Organization (WHO), countries across Asia Pacific have substantially improved institutional childbirth rates and neonatal healthcare coverage, enabling earlier detection of congenital disorders. Increasing clinical research, improved reimbursement for orphan drugs, and expansion of specialized pediatric hospitals are expected to drive rapid regional growth throughout the forecast period.

China Biliary Atresia Treatment Market Trends

China is expected to lead the Asia Pacific market and is projected to reach approximately US$0.13 billion by 2026. China records one of the world's largest numbers of pediatric liver disease patients due to its large birth population. National Health Commission initiatives have expanded pediatric specialty hospitals and pediatric surgery capacity across major provinces. China has also significantly increased liver transplantation capability through leading centers in Beijing, Shanghai, and Guangzhou.

According to the China Organ Transplant Response System (COTRS), liver transplantation activity has steadily expanded with improvements in national organ donation programs. Growing investment in rare disease diagnosis, increasing adoption of minimally invasive pediatric surgery, and expanding clinical research collaborations continue to strengthen China's leadership in the regional biliary atresia treatment market.

India Biliary Atresia Treatment Market

India is anticipated to be the fastest-growing country in Asia Pacific, with an expected CAGR of 8.5% during 2026–2033. India continues to expand pediatric liver transplantation through leading institutions such as the Institute of Liver and Biliary Sciences (ILBS), Medanta, and Apollo Hospitals. According to the National Organ and Tissue Transplant Organization (NOTTO), organ donation and transplantation activities have increased steadily in recent years following nationwide awareness initiatives.

The Government of India's National Policy for Rare Diseases has also improved financial support for selected rare disorders and strengthened diagnosis at tertiary care centers. Rising healthcare expenditure, expanding pediatric specialty hospitals, increasing awareness among pediatricians regarding early Kasai surgery, and growing access to advanced liver transplantation are expected to support rapid market expansion across the country.

The global biliary atresia treatment market remains moderately fragmented, comprising specialized pharmaceutical companies focused on rare pediatric liver disease alongside larger diversified healthcare companies providing surgical and transplant-related technology. Mirum Pharmaceuticals and Ipsen, including its Albireo Pharma subsidiary, maintain leadership within the emerging pharmacological therapy segment through bile acid-modulating drug development, while Medtronic plc and Olympus Corporation supply surgical instrumentation used in the Kasai procedure and transplant surgery.

TransMedics, Inc. continues to advance organ preservation technology relevant to pediatric liver transplantation. Emerging competitive strategies include expanded rare disease clinical trial investment, surgical technology innovation, and continued generic pharmacological therapy portfolio development across emerging markets.

Key Industry Developments:

• In May 2026, AstraZeneca presented new Phase III clinical trial data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, highlighting advances across liver, breast, and bladder cancers, as well as its investigational rare disease portfolio. Among the presentations, the company showcased data for a potential first-in-class therapy for rare cholestatic liver diseases, reinforcing its commitment to expanding treatment options for patients with rare hepatic disorders, including conditions such as biliary atresia.
• In March 2026, Mirum Pharmaceuticals announced that it had completed patient enrollment in its Phase 3 EXPAND clinical trial evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus associated with additional rare cholestatic liver diseases, including biliary atresia.